Par Pharmaceutical gets FDA approval of Vasostrict
Vasostrict is the first and only vasopressin injection, USP, product with an NDA approved by the US FDA and it is indicated to increase blood pressure in adults
Vasostrict is the first and only vasopressin injection, USP, product with an NDA approved by the US FDA and it is indicated to increase blood pressure in adults
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. This is the company’s second approval to start a Phase
The open-label trial (Study 204) is designed to evaluate the safety of eteplirsen over 96 weeks of dosing, and will be conducted in DMD patients who are non-ambulant
Severe aplastic anaemia is a rare disorder in which the bone marrow fails to make enough new blood cells. Currently, there are no approved therapies available for SAA
Following approval for the IND application, the company will conduct a Phase I/II trial of ADXS-HPV alone or in combination with MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736,
Ophthotech now has exclusive license to investigate the potential of AVEO’s tivozanib, outside of Asia for the potential treatment of non-oncologic diseases of the eye. As part of
Currently, the company is conducting an international, randomized Phase III trial of TH-302 in these patients in partnership with the Sarcoma Alliance for Research through Collaboration (SARC) and
Around 316 healthy adults aged 18-40 were enrolled in the Phase I trial and they were each evaluated for vaccine tolerability and immune response at 21 days post-vaccination.
The Israeli firm is a developer, manufacturer and marketer of new bio-active lipid based nutritional ingredients and medical foods. Around 171 patients between the ages of 18 and
As part of the deal, BioAtla will direct BioDuro’s efforts to advance these compounds through the preclinical and Phase I clinical phases and each candidate will be licensed